Calamos Wealth Management LLC Has $15.14 Million Holdings in Boston Scientific Corporation $BSX

Calamos Wealth Management LLC boosted its stake in Boston Scientific Corporation (NYSE:BSX) by 52.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 155,038 shares of the medical equipment provider’s stock after purchasing an additional 53,252 shares during the period. Calamos Wealth Management LLC’s holdings in Boston Scientific were worth $15,136,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of BSX. FWL Investment Management LLC bought a new stake in shares of Boston Scientific in the 2nd quarter valued at about $26,000. Sound Income Strategies LLC lifted its stake in shares of Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 120 shares during the period. Steph & Co. bought a new stake in Boston Scientific in the third quarter valued at approximately $25,000. 1248 Management LLC acquired a new stake in Boston Scientific during the 1st quarter valued at approximately $26,000. Finally, Kilter Group LLC acquired a new stake in Boston Scientific during the 2nd quarter valued at approximately $30,000. 89.07% of the stock is owned by institutional investors.

Insider Transactions at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. This trade represents a 42.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. The trade was a 21.90% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 93,095 shares of company stock valued at $9,305,450 over the last ninety days. 0.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on BSX. Canaccord Genuity Group dropped their price target on shares of Boston Scientific from $132.00 to $131.00 and set a “buy” rating on the stock in a research report on Wednesday, December 17th. The Goldman Sachs Group restated a “buy” rating and issued a $124.00 target price on shares of Boston Scientific in a report on Wednesday, October 22nd. Leerink Partners increased their price target on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday, October 8th. Finally, Evercore ISI restated an “outperform” rating on shares of Boston Scientific in a research report on Wednesday, October 22nd. Two analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Boston Scientific has a consensus rating of “Buy” and a consensus price target of $124.85.

Boston Scientific Price Performance

BSX stock opened at $95.98 on Wednesday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. The company’s 50-day moving average is $98.36 and its 200-day moving average is $101.05. The stock has a market capitalization of $142.28 billion, a PE ratio of 51.32, a price-to-earnings-growth ratio of 1.93 and a beta of 0.67. Boston Scientific Corporation has a 1 year low of $85.98 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The business had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The firm’s revenue was up 20.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Equities research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.